NCT06866236Not yet recruitingPhase 2/3
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 8 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 3000 (estimated)
- First submitted
- 4 Mar 2025
- Start date
- Oct 2025
- Primary completion date
- Oct 2026
- Lead sponsor
- Ebima Clifford Okundaye
- Diseases
- Chronic kidney disease
- NCT number
- NCT06866236
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 3000
- From Oct 2025 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Symptomatic renal failure
- Presence of any suspected Acute renal failure superimposed
Other
- Rapid rate of decline in kidney function of \> 20 % over last one year
- Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
- No known reversible cause of renal decline
Who the study is looking for
- Inclusion criteria
- Patient with Chronic kidney disease
- Estimated Glomerular function by MDRD of less than 60mls/min
- Patients with declining renal function ( as measured by eGFR by MDRD )
- Rate of decline of eGFR over the last one year of less than 20%
- Negative Serology markers for CKD etiology
- Provider perceived adherence to study follow up
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neukidney Inc Coordinator of this site? Confirm its status | Pasedena | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.